NASDAQ: CORV
TSX: CORV
VANCOUVER, Aug. 1, 2018 /CNW/ - Correvio Pharma Corp.
(NASDAQ:CORV) (TSX:CORV), a revenue-generating, specialty
pharmaceutical company focused on commercializing hospital drugs,
today announced that Dr. William
Hunter, President and Chief Executive Officer of Correvio,
will present at the Canaccord Genuity 38th Annual Growth
Conference. The presentation will take place at the
InterContinental Boston on Wednesday, August
8, 2018 at 12:00 p.m. EST in
Boston, MA.
The webcast of Dr. Hunter's presentation can be accessed through
the following link: http://wsw.com/webcast/canaccord30/corv.to/
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution network
covering over 60 countries worldwide, Correvio develops, acquires
and commercializes brands for the in-hospital, acute care market
segment. The Company's portfolio of approved and marketed brands
includes: Xydalba™ (dalbavancin hydrochloride), for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole
medocaril sodium), a cephalosporin antibiotic for the treatment of
community- and hospital-acquired pneumonia (CAP, HAP);
Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction
of thrombotic cardiovascular events in patients with acute coronary
syndrome, and Esmocard® and Esmocard Lyo®
(esmolol hydrochloride), a short-acting betablocker used to control
rapid heart rate in a number of cardiovascular indications.
Correvio's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to
deliver treprostinil, the world's leading treatment for pulmonary
arterial hypertension.
Correvio is traded on the Nasdaq Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit
the Company's web site at www.correvio.com.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International
Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed Therapeutics, Inc.
and used under license.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/correvio-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-300689822.html
SOURCE Correvio Pharma Corp